OR WAIT null SECS
Cynthia A. Challener is a contributing editor to Pharmaceutical Technology.
The decision to use disposable bioreactors is now driven by commercial rather than technological considerations.
Dramatic increases in protein titers from cell culture processes have enabled downsizing of upstream bioprocesses and facilitated the adoption of single-use bioreactors for biopharmaceutical manufacturing.
Manufacturers of disposable bioreactors have continually worked to improve their systems to meet evolving needs for biologic drug substance production.
This article explores recent advances in disposable bioreactor technology, the limitations that remain, and efforts that are underway to address them.